GPRC5D-Targeting Approach Positions Company to Expand Post-BCMA Treatment Options
As reported on Fierce BioTech, Bristol Myers Squibb announced positive results from its pivotal Quintessential trial evaluating arlocabtagene autoleucel, a genetically modified T-cell therapy directed against the GPRC5D protein. The trial successfully achieved its primary objective, validating the approach as physicians seek alternatives for patients whose myeloma has proven resistant to currently available options.
The competitive landscape in multiple myeloma has shifted dramatically as BCMA-targeted therapies—including CAR-T cells, bispecific antibodies, and conjugated monoclonal antibodies—have transformed treatment paradigms. Yet disease progression remains inevitable for many patients, creating clinical demand for therapies with different mechanisms. BMS’s strategy addresses this need by targeting GPRC5D, a distinct antigen expressed on myeloma cells.
Quintessential enrolled heavily pretreated patients—those with prior exposure to immunomodulatory agents, proteasome inhibitors, anti-CD38 antibodies, and BCMA-directed interventions. The trial met its co-primary endpoint measuring disease response rates and confirmed efficacy on a key secondary measure of complete remission.
Safety Profile and Competitive Positioning
Early data supporting arlocabtagene’s clinical development suggested a potentially more favorable tolerability profile compared to bispecific antibodies, particularly regarding treatment-related adverse events. As a single-administration cell therapy, the approach contrasts with continuous dosing regimens required by antibody-based competitors.
Johnson & Johnson’s Talvey, a bispecific antibody targeting the same GPRC5D pathway, demonstrated a response rate of 72% in its registrational trial. BMS will present additional Quintessential data at an upcoming medical conference, providing a more complete basis for comparative assessment.
BMS is simultaneously advancing a Phase 3 comparative effectiveness study against standard-of-care regimens in less heavily pretreated patients, with readouts anticipated in 2028. The broader competitive field includes development programs from AbbVie, AstraZeneca, Legend Biotech, and Sanofi, alongside J&J’s multispecific antibody candidates engaging both BCMA and GPRC5D.
